RECRUITINGINTERVENTIONAL

Micropulsed Laser in Patients With Macular Oedema in Retinal Dystrophies

Treatment of Macular Oedema in Patients With Hereditary Retinal Dystrophies by Applying the Micropulsed Subthreshold Laser

About This Trial

The purpose of this study is to investigate whether subthreshold treatment with micropulsed laser can be effective in resolving macular edema in patients with inherited retinal dystrophy. Visits will be performed after 1, 3, 6, 9, 12, 18, and 24 months after treatment. Laser treatment will be performed on the day of the first visit, and its repetition at subsequent visits between months 3 and 12 will be evaluated. Evaluations of treatment effects will include: * comprehensive ophthalmologic examination * multifocal electroretinogram * OCT examination * OCT-angiography examination * retinography Primary endpoint. \- central retinal thickness, measured by OCT

Who May Be Eligible (Plain English)

Who May Qualify: - Patients with inherited retinal disease - Age between 18 and 80 years - Conclusive molecular genetic study for IRD - Male or female patient - Presence of macular oedema assessed by sd-OCT with reduction ≤ 20% after 3 months of diuretics or draining supplements or 4 months after last anti-VEGF or steroid injection - Phakic and pseudophakic patients - Central Retinal thickness \> 320 microns in men and \> 305 microns in women - willing to sign a consent form freely granted and acquired before the start of the study - Participant has the ability to understand and willingness to follow study instructions and is likely to complete all required visits and procedures. Who Should NOT Join This Trial: - Patients with cataract extraction prior to 6 months - Patients with IOP ≥ 20 mmHg - Patients with a clinical diagnosis of retinal dystrophy of unproven genetic origin - Patients with diabetes - Patients with central serous chorioretinosis, retinal vein occlusion, age-related degeneration - Patients with current or previous vitreo-retinal pathology or with indication for vitreo-retinal surgical therapy (tractional oedema) - Patients with a lack of target fixation at 32 cm - Pregnant women Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language

Inclusion Criteria: * Patients with inherited retinal disease * Age between 18 and 80 years * Conclusive molecular genetic study for IRD * Male or female patient * Presence of macular oedema assessed by sd-OCT with reduction ≤ 20% after 3 months of diuretics or draining supplements or 4 months after last anti-VEGF or steroid injection * Phakic and pseudophakic patients * Central Retinal thickness \> 320 microns in men and \> 305 microns in women * Informed consent freely granted and acquired before the start of the study * Participant has the ability to understand and willingness to follow study instructions and is likely to complete all required visits and procedures. Exclusion Criteria: * Patients with cataract extraction prior to 6 months * Patients with IOP ≥ 20 mmHg * Patients with a clinical diagnosis of retinal dystrophy of unproven genetic origin * Patients with diabetes * Patients with central serous chorioretinosis, retinal vein occlusion, age-related degeneration * Patients with current or previous vitreo-retinal pathology or with indication for vitreo-retinal surgical therapy (tractional oedema) * Patients with a lack of target fixation at 32 cm * Pregnant women

Treatments Being Tested

DEVICE

subthreshold treatment with micropulsed laser

The laser instrument used is the Q 577® Laser System, Iridex, wavelength 577 yellow. The standard pattern used is: * Power: 5% Duty Cycle * Power 250 mw * Pulse duration 200 ms * Spot size 100 micron * Pattern spacing 0.0 confluente, griglie 7x7

Locations (1)

IRCSS Fondazione G:B:Bietti

Rome, RM, Italy